Anti-CD5 monoclonal antibody [FITC] (DMABT-45229MS)

Mouse Anti-Sheep CD5 monoclonal antibody for FC

Additional Formats Available

Specifications


Host Species
Mouse
Antibody Isotype
IgG1
Clone
36.02
Species Reactivity
Sheep
Immunogen
Ovine thymocytes
Conjugate
FITC

Applications


Application Notes
FCM: Neat - 1/10
*Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.

Target


Alternative Names
T1; LEU1
Entrez Gene ID
UniProt ID

Citations


Have you cited DMABT-45229MS in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Mouse IgG1 Isotype Control [FITC] DAGIC1498 FC Mouse PDF Inquiry

References


Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis

FRONTIERS IN IMMUNOLOGY

Authors: Mestre, Leyre; Javier Carrillo-Salinas, Francisco; Mecha, Miriam; Feliu, Ana; Espejo, Carmen; Carlos Alvarez-Cermeno, Jose; Maria Villar, Luisa; Guaza, Carmen

Gut microbiota dysbiosis has been implicated in MS and other immune diseases, although it remains unclear how manipulating the gut microbiota may affect the disease course. Using a well-established model of progressive MS triggered by intracranial infection with Theiler's murine encephalomyelitis virus (TMEV), we sought to determine whether dysbiosis induced by oral antibiotics (ABX) administered on pre-symptomatic and symptomatic phases of the disease influences its course. We also addressed the effects of microbiota recolonization after ABX withdrawn in the presence or absence of probiotics. Central and peripheral immunity, plasma acetate and butyrate levels, axon damage and motor disability were evaluated. The cocktail of ABX prevented motor dysfunction and limited axon damage in mice, which had fewer CD4(+) and CD8(+) T cells in the CNS, while gut microbiota recolonization worsened motor function and axonal integrity. The underlying mechanisms of ABX protective effects seem to involve CD4(+)CD39(+) T cells and CD5(+)CD1d(+) B cells into the CNS. In addition, microglia adopted a round amoeboid morphology associated to an anti-inflammatory gene profile in the spinal cord of TMEV mice administered ABX. The immune changes in the spleen and mesenteric lymph nodes were modest, yet ABX treatment of mice limited IL-17 production ex vivo. Collectively, our results provide evidence of the functional relevance of gut microbiota manipulation on the neurodegenerative state and disease severity in a model of progressive MS and reinforce the role of gut microbiota as target for MS treatment.

Primary cutaneous gamma delta T-cell lymphoma with unusual immunophenotype: A case report and review of published work

JOURNAL OF DERMATOLOGY

Authors: Kamijo, Hiroaki; Miyagaki, Tomomitsu; Norimatsu, Yurie; Awaji, Kentaro; Oka, Tomonori; Suga, Hiraku; Sugaya, Makoto; Sato, Shinichi

Primary cutaneous gamma delta T-cell lymphoma (CGD-TCL) is a rare form of primary cutaneous lymphoma. The histopathological features of CGD-TCL are still unclear because of its rarity. Here, we report a case of a 77-year-old Japanese man who presented with a 9-month history of erythematous plaques on his left forearm. Skin biopsy specimens revealed the infiltration of atypical medium/large-sized lymphocytes from the epidermis to the deep dermis. Atypical lymphocytes were positive for CD3, CD5, CD8 and V delta 1, and negative for CD4, CD7, CD56, EBER-ISH, intracellular antigen-1, granzyme B and perforin. CD30 was partially expressed. We also reviewed 246 cases of CGD-TCL from the published work. CD4(-)CD8(-) double-negative cases were 113 of 196 cases (57.6%), followed by CD4(-)CD8(+) cases (52/196, 26.5%). CD5 was expressed in 25.8% of the cases (34/132). At least one cytotoxic molecule marker was expressed in 150 of 160 cases (93.8%). Some cases showed an indolent clinical course, especially in mycosis fungoides-like CGD-TCL cases. CD5 positivity and lack of cytotoxic molecule expression could be associated with a better prognosis. In addition, CD30 expression was found in approximately half of CGD-TCL cases (51/112 cases), suggesting that brentuximab vedotin could be a good treatment option for such patients. Further studies with more cases with detailed clinical and pathological information are necessary to elucidate the etiology and prognostic markers of this entity.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket